Medicare AdvantageCoverageMedium impact
MA07.044b, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Allergy & Immunology, Family Medicine +2 more·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.044b regarding measurement of exhaled nitric oxide and breath condensate for asthma and respiratory disorder diagnosis has been reissued effective October 1, 2025. This policy update affects coverage and billing requirements for these specialized respiratory diagnostic tests.
Action Required
By October 1, 2025: Billing team must review updated policy MA07.044b for exhaled nitric oxide and breath condensate measurement procedures. Verify current coverage criteria and documentation requirements for Medicare Advantage plans. Update billing protocols and prior authorization processes as specified in the full policy document.